Discovery and Development of Obinutuzumab (GAZYVA, GAZYVARO), a Glycoengineered Type II Anti-CD20 Antibody for the Treatment of Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia

MLA

Ekkehard Mössner, et al. Discovery and Development of Obinutuzumab (GAZYVA, GAZYVARO), a Glycoengineered Type II Anti-CD20 Antibody for the Treatment of Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia. Apr. 2018. EBSCOhost, https://doi.org/10.1002/9783527808694.ch9.

APA

Ekkehard Mössner, Marina Bacac, Pablo Umana, Christian Klein, & Günter Fingerle-Rowson. (2018). Discovery and Development of Obinutuzumab (GAZYVA, GAZYVARO), a Glycoengineered Type II Anti-CD20 Antibody for the Treatment of Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia. https://doi.org/10.1002/9783527808694.ch9

Chicago

Ekkehard Mössner, Marina Bacac, Pablo Umana, Christian Klein, and Günter Fingerle-Rowson. 2018. “Discovery and Development of Obinutuzumab (GAZYVA, GAZYVARO), a Glycoengineered Type II Anti-CD20 Antibody for the Treatment of Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia,” April. doi:10.1002/9783527808694.ch9.